Publications by authors named "Etienne Gabriel"

Claim this Profile
A
Asciminib Demonstrates Superior Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia in the ASC4FIRST Trial.
Jorge E Cortes, Timothy P Hughes, Jianxiang Wang, Dong-Wook Kim, Dennis Dong Hwan Kim, Gabriel Etienne

Blood· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thromboinflammation is associated with high thrombotic risk in patients with newly diagnosed myeloproliferative neoplasms.
Alexandre Guy, Olivier Mansier, Matisse Decilap, Alexandre Catherineau, Geoffrey Garcia, Gabriel Etienne

Leukemia· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment-free remission in chronic myeloid leukemia with rare ABL1 gene fusions: Real-life study from the French CML group Fi-LMC.
Hyacinthe Johnson-Ansah, Aude Charbonnier, Gabriel Etienne, Lydia Roy, Laurence Legros, Gabrielle Roth-Guépin

Leuk Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutation of Epigenetic Regulators at Diagnosis Is an Independent Predictor of Tyrosine Kinase Inhibitor Treatment Failure in Chronic Myeloid Leukemia: A Report From the RESIDIAG Study.
Hippolyte Guerineau, Jean-Michel Cayuela, Stéphanie Dulucq, Violaine Tran Quang, Sihem Tarfi, Gabriel Etienne

Am J Hematol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.
Andreas Hochhaus, Jianxiang Wang, Dong-Wook Kim, Dennis Dong Hwan Kim, Jiri Mayer, Gabriel Etienne

N Engl J Med· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CXCL8 secreted by immature granulocytes inhibits WT hematopoiesis in chronic myelomonocytic leukemia.
Paul Deschamps, Margaux Wacheux, Axel Gosseye, Margot Morabito, Arnaud Pagès, Gabriel Etienne

J Clin Invest· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial.
Fabio Efficace, Francois-Xavier Mahon, Johan Richter, Alfonso Piciocchi, Marta Cipriani, Gabriel Etienne

Leukemia· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results.
Jorge E Cortes, Koji Sasaki, Dong-Wook Kim, Timothy P Hughes, Gabriel Etienne

Leukemia· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission.
Francois-Xavier Mahon, Markus Pfirrmann, Stéphanie Dulucq, Andreas Hochhaus, Panayiotis Panayiotidis, Gabriel Etienne

J Clin Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in chronic phase chronic myelogenous leukaemia patients.
Vincent Alcazer, Stéphane Morisset, Delphine Rea, Laurence Legros, Stéphanie Dulucq, Gabriel Etienne

Br J Haematol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Optimizing the use of bosutinib in patients with chronic-phase chronic myeloid leukemia: Recommendations of a panel of experts from the Fi-LMC (French CML working group)].
Delphine Rea, Emilie Cayssials, Aude Charbonnier, Valérie Coiteux, Gabriel Etienne

Bull Cancer· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose optimisation of ponatinib in chronic phase chronic myeloid leukemia.
Françoise Huguet, Delphine Réa, Emilie Cayssials, Gabriel Etienne, Franck-Emmanuel Nicolini

Expert Rev Hematol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Multicenter Retrospective Chart Review Study of Treatment and Disease Patterns and Clinical Outcomes of Patients with Chronic-Phase Chronic Myeloid Leukemia in Third-Line Treatment or with T315I Mutation.
Franck-Emmanuel Nicolini, Françoise Huguet, Lynn Huynh, Churong Xu, Christophe Bouvier, Gabriel Etienne

Cancers (Basel)· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia.
Marie Balsat, Vincent Alcazer, Gabriel Etienne, Françoise Huguet, Marc Berger

Leuk Res· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment-free remission period after imatinib discontinuation: Results of the French Nilo post-STIM study.
Stéphanie Dulucq, Françoise Rigal-Huguet, Franck E Nicolini, Pascale Cony-Makhoul, Martine Escoffre-Barbe, Gabriel Etienne

Br J Haematol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
One-Year Follow-Up of Seroprevalence of SARS-CoV-2 Infection and Anxiety among Health Workers of a French Cancer Center: The PRO-SERO-COV Study.
Brice Richez, Coralie Cantarel, Françoise Durrieu, Isabelle Soubeyran, Julie Blanchi, Gabriel Etienne

Int J Environ Res Public Health· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA-PegIFN study).
Lydia Roy, Jean-Claude Chomel, Joëlle Guilhot, Agnès Guerci-Bresler, Martine Escoffre-Barbe, Gabriel Etienne

Br J Haematol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial.
Stéphanie Dulucq, Franck E Nicolini, Delphine Rea, Pascale Cony-Makhoul, Aude Charbonnier, Gabriel Etienne

Haematologica· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Practical management of PARP inhibitors: A French DELPHI consensus].
Frédéric Selle, Jean-Jacques Boffa, Gabriel Etienne, Antoine Angelergues, Paule Augereau

Bull Cancer· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience.
Vincent Marmouset, Justine Decroocq, Sylvain Garciaz, Gabriel Etienne, Amine Belhabri

Clin Cancer Res· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second- or third-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukemia in general population: Is there a real benefit?
Jim Canet, Pascale Cony-Makhoul, Sébastien Orazio, Edouard Cornet, Xavier Troussard, Gabriel Étienne

Cancer Med· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Lotus Flower: Black students learning and loving through the anti-Black labyrinth of higher ed.
Kayonne Christy, Gabriel E Etienne

Can Rev Sociol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.
Hagop M Kantarjian, Timothy P Hughes, Richard A Larson, Dong-Wook Kim, Surapol Issaragrisil, Gabriel Etienne

Leukemia· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients.
Philippe Rousselot, Luigina Mollica, Joëlle Guilhot, Agnès Guerci, Franck E Nicolini, Gabriel Etienne

Br J Haematol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relevance of treatment-free remission recommendations in chronic phase chronic leukemia patients treated with frontline tyrosine kinase inhibitors.
Gabriel Etienne, Carole Faberes, Fréderic Bauduer, Didier Adiko, François Lifermann

Cancer Med· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis